TORONTO, ONTARIO--(Marketwired - March 8, 2017) - Revive Therapeutics Ltd. ("Revive" or the "Company") (TSX VENTURE:RVV)(OTCQB:RVVTF), a company focused on the research, development and commercialization of novel treatments for serious and unmet medical needs, today announced that Yanlin Wang, M.D., Ph.D., will join the Company as a Scientific Advisor for cannabinoid-based therapeutics targeting kidney diseases.
"I am pleased that Dr. Wang has joined Revive to assist with advancing the research and development of our cannabinoid-based research initiatives targeting kidney diseases," said Craig Leon, Chief Executive Officer of Revive. "Dr. Wang has experience with a number of research kidney models that will help to advance developments to the clinic and he will be instrumental in assisting Revive's initiatives in the product and clinical development of cannabinoid-based therapeutics for kidney diseases."
"I am very excited to be a part of the Revive team as we work to advance the cannabinoid research for kidney diseases," said Dr. Yanlin Wang. "I am pleased to utilize my expertise in a variety of research models of kidney injury and fibrosis and to investigate potentially novel cannabinoid- based therapeutics that address the unmet medical needs in kidney diseases."
Dr. Yanlin Wang is an Associate Professor of Medicine and Director of Basic Research in the Selzman Institute for Kidney Health and Section of Nephrology of the Department of Medicine at Baylor College of Medicine. He is board certified by the American Board of Internal Medicine in Internal Medicine and Nephrology and is a Fellow of the American Society of Nephrology. Dr. Wang is an active clinician; he regularly treats patients with kidney diseases at Baylor affiliated hospitals and teaches medical students, residents, and fellows at Baylor College of Medicine. Dr. Wang is also a scientist. His research interest is to elucidate the cellular and molecular mechanisms of acute kidney injury and chronic renal fibrosis with a focus on the role of immune-inflammatory dysregulation in the pathogenesis of kidney injury and fibrosis. He completed a postdoctoral fellowship at Harvard Medical School where he studied the role of inflammation in cardiac remodeling, which was supported by a NIH postdoctoral fellowship. After medical residency training, he completed a clinical fellowship in Nephrology at Baylor College of Medicine. During that period, he studied the role of stanniocalcin-1 in the regulation of oxidative stress and the role of myeloid fibroblast precursors in the pathogenesis of cardiac fibrosis in the setting of chronic kidney disease. He was awarded a NIH Clinical Scientist Career Development Award. After joining the faculty in Nephrology at Baylor, he has been investigating novel factors initiating and controlling acute kidney injury and chronic renal fibrosis. His research projects have been funded by the American Heart Association, the National Institutes of Health, and the US Department of Veterans Affairs. Dr. Wang is currently serving as an editorial board member for a number of biomedical journals.
About Revive Therapeutics Ltd.
Revive Therapeutics Ltd. (TSX VENTURE:RVV) (OTCQB:RVVTF) is focused on the research, development and commercialization of novel treatments for serious and unmet medical needs by identifying and investigating potential drugs and plant-based therapies, such as cannabinoids, that may be repurposed for new indications, be delivered in a different way, combined with existing drugs, or be developed as new chemical entities or prodrugs. Additional information on Revive is available at www.ReviveThera.com.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This news release includes certain information and statements about management's view of future events, expectations, plans and prospects that constitute "forward-looking statements", which are not comprised of historical facts. Forward-looking statements may be identified by such terms as "believes", "anticipates", "intends", "expects", "estimates", "may", "could", "would", "will", or "plan", and similar expressions. Specifically, forward-looking statements in this news release include, without limitation, statements regarding: the joint venture with InMed Pharmaceuticals Inc. for development of cannabinoid-based therapies for targeting kidney diseases and entering into a definitive joint venture agreement; the granting of a patent for Bucillamine for the treatment of gout; the potential efficacy and commercial viability of Bucillamine for treatment of gout and Bucillamine for the treatment of Cystinuria; expansion of the Bucillamine clinical testing program; the Company's drug research and development, and commercialization plans; the Company's research, development and commercialization plans for plant-based therapies, including cannabinoids; the timing of operations; and estimates of market conditions. These statements involve known and unknown risks, uncertainties, and other factors that may cause actual results or events, performance, or achievements of Revive to differ materially from those anticipated or implied in such forward-looking statements. The Company believes that the expectations reflected in these forward-looking statements are reasonable, but there can be no assurance that actual results will meet management's expectations. In formulating the forward-looking statements contained herein, management has assumed: that business and economic conditions affecting Revive will continue substantially in the ordinary course and will be favourable to Revive; that clinical testing results will justify commercialization of the Company's drug candidates; that Revive will be able to obtain all requisite regulatory approvals to commercialize its drug candidates; that such approvals will be received on a timely basis; and, that Revive will be able to find suitable partners for development and commercialization of its drug repurposing candidates on favourable terms. Although these assumptions were considered reasonable by management at the time of preparation, they may prove to be incorrect.
Factors that may cause actual results to differ materially from those anticipated by these forward-looking statements include: the inability to conclude a joint venture with InMed Pharmaceuticals Inc. on terms which are commercially reasonable or at all; uncertainties associated with obtaining regulatory approval to perform clinical trials and market products; the need to establish additional corporate collaborations, distribution or licensing arrangements; the Company's ability to raise additional capital if and when necessary; intellectual property disputes; increased competition from pharmaceutical and biotechnology companies; changes in equity markets, inflation, and changes in exchange rates; and other factors as described in detail in Revive's Management's Discussion & Analysis for the period ended June 30, 2016 and Revive's other public filings, all of which may be viewed on SEDAR (www.sedar.com). Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. Except as required by law, Revive disclaims any intention and assumes no obligation to update or revise any forward-looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking statements or otherwise.
Neither the TSX-V nor its Regulation Services Provider (as that term is defined in the policies of the TSX-V) accepts responsibility for the adequacy or accuracy of this release.